AnaptysBio, Inc. ANAB License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s license — revenue?
- AnaptysBio, Inc. (ANAB) reported license — revenue of $0 in Q1 2026.
- How has AnaptysBio, Inc.'s license — revenue changed year-over-year?
- AnaptysBio, Inc.'s license — revenue decreased by 100.0% year-over-year, from $9.6M to $0.
- What does license — revenue mean?
- This metric captures the total revenue recognized from licensing intellectual property or technology rights to third-party customers, excluding any pass-through taxes. It serves as a primary indicator of the commercial value of the company's proprietary antibody pipeline and research platform. Monitoring this figure helps stakeholders evaluate the success of the company's business model in converting clinical-stage assets into contractual revenue streams.